iwAL 2018: a plethora of new drugs & amp; their impact on trial design
The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, was a great success, with the experts in attendance expressing their surprise that this was the first such meeting...
Author: VJHemOnc
Added: 03/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 1, 2018 Category: Cancer & Oncology Source Type: podcasts
Off-the-shelf anti-CD7 CAR T-cells for T-cell malignancies
CAR T-cells are a very promising therapeutic for hematological malignancies, with more in development for B-cell compared with T-cell malignancies. At the 1st International Workshop on Acute Leukemias...
Author: VJHemOnc
Added: 03/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 1, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy for AML and ALL: checkpoint inhibitors & amp; CAR T-cells for B-cell ALL
Immunotherapy is an exciting area, with advocates, sceptics and those who remain undecided without further research. The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, F...
Author: VJHemOnc
Added: 03/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 1, 2018 Category: Cancer & Oncology Source Type: podcasts
Advances in AML understanding: APL therapy, immunotherapy and maintenance therapy
Our understanding of acute myeloid leukemia (AML) has made great strides in recent years, informing the direction of therapeutic strategies. In this session, filmed at the 1st International Workshop o...
Author: VJHemOnc
Added: 03/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 1, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD for acute leukemias: opinion from both sides of the Atlantic
The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, hosted though-provoking discussion on the topic of minimal residual disease (MRD). In this panel discussion, exper...
Author: VJHemOnc
Added: 03/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 1, 2018 Category: Cancer & Oncology Source Type: podcasts
iwAL 2018 day 1 discussion: treatment strategies in pediatric and adult ALL
The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, hosted an exciting session on treatment strategies in acute lymphoblastic leukemia (ALL). In this panel discussion...
Author: VJHemOnc
Added: 03/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 1, 2018 Category: Cancer & Oncology Source Type: podcasts
Acute leukemias: is MRD already a surrogate for survival?
The use of minimal residual disease (MRD) in the management of acute leukemias is a hotly debated topic. Despite the potential of MRD status as a prognostic marker and measure of disease, there are a ...
Author: VJHemOnc
Added: 02/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 28, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy for AML and ALL: checkpoint inhibitors, off-the-shelf anti-CD7 CAR T-cells and more
Immunotherapy is an exciting area, with both advocates and sceptics, in addition to those who remain undecided without further research. The 1st International Workshop on Acute Leukemias (iwAL), held ...
Author: VJHemOnc
Added: 02/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Next steps in gaining CLARITY on CLL
With new developments in the treatment of patients with chronic lymphocytic leukemia (CLL), is there a possibility of eradicating the disease? In this interview, Francesco Forconi, MD, DM, PhD, FRCPat...
Author: VJHemOnc
Added: 02/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Targeted treatments for AML: the revolution
Exciting advancements in acute myeloid leukemia (AML) research were discussed during the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. There has recentl...
Author: VJHemOnc
Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Advancements in APL treatment: oral ATO, MRD and treatment objectives
Despite the remarkable progress being made in the treatment of patients with acute promyelocytic leukemia (APL), a high rate of early death remains a major obstacle worldwide, particularly in developi...
Author: VJHemOnc
Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel ALL treatment strategies: inotuzumab ozogamicin
Over the past year, several exciting new agents for the treatment of acute lymphoblastic leukemia (ALL) have been approved. In this interview, Elias Jabbour, MD, of the University of Texas MD Anderson...
Author: VJHemOnc
Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel ALL treatment strategies: blinatumomab
There have recently been a number of major drug approvals for the treatment of acute lymphoblastic leukemia (ALL). One such approval was that of blinatumomab based on data from pivotal studies, includ...
Author: VJHemOnc
Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Rationale and results behind the use of breakthrough therapy-designated E-selectin antagonist for AML
The binding of E-selectin to leukemic cells has been shown to promote cell survival and chemotherapy resistance in acute myeloid leukemia (AML). In this interview, Daniel DeAngelo, MD, PhD, of Dana-Fa...
Author: VJHemOnc
Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts
Whats next for inotuzumab ozogamicin in ALL?
The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin was approved for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), the most common form of ALL, based on data from the I...
Author: VJHemOnc
Added: 02/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 20, 2018 Category: Cancer & Oncology Source Type: podcasts
